Cargando…
Etanercept leads to a rapid recovery of a Dabrafenib‐/Trametinib‐associated toxic epidermal necrolysis‐like severe skin reaction
Targeted therapy with BRAF‐ and MEK‐Inhibitors (BRAFi, MEKi) provides an excellent therapeutic option for patients with malignant melanomas with a BRAF‐Mutation. Mild cutaneous adverse events have been common under the BRAF‐ and MEK‐Inhibitor therapy, on the contrary, severe cutaneous adverse reacti...
Autores principales: | Yordanova, Krista, Pföhler, Claudia, Schweitzer, Luca F., Bourg, Catherine, Adam, Leonie, Vogt, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892424/ https://www.ncbi.nlm.nih.gov/pubmed/36751314 http://dx.doi.org/10.1002/ski2.185 |
Ejemplares similares
-
Ocular toxicity due to Trametinib and Dabrafenib
por: Sarny, Stephanie, et al.
Publicado: (2017) -
Dabrafenib/trametinib: Cardiac toxicity: case report
Publicado: (2021) -
Cephradine-Induced Toxic Epidermal Necrolysis: A Case Report of Treatment With Etanercept
por: Hubail, Rawan, et al.
Publicado: (2022) -
Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
por: Minor, David R., et al.
Publicado: (2015) -
Dabrafenib- and trametinib-associated glomerular toxicity: A case report
por: Jo, Eunmi, et al.
Publicado: (2022)